PresentationGood morning, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Very happy to have our next session led by CEO of GE HealthCare, Pete Arduini. Pete will do a presentation followed by some Q&A. Pete?Peter ArduiniPresident, CEO & Director I guess it's still good morning, good afternoon for those on the webcast. Great to be out to a sunny JPMorgan. Just kind of kicking off, we'll use, obviously, some forward-looking statements here. A lot of our financials will be Q3 year-to-date, and ...

PresentationHello, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Very happy to host our next session with Insulet. CEO, Ashley McEvoy, will do a presentation followed by some Q&A.Ashley McEvoyCEO, President & Director Thank you, Robbie. Good morning, everyone. It's a pleasure to be here. I am Ashley McEvoy, President and CEO of Insulet and really looking forward to sharing our story and why we are so energized about the present and importantly, the future. Before we begin, please note our s ...

PresentationGood morning, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Thanks for joining us at the first session to kick off the 2026 JPMorgan Healthcare Conference. I'll give a warm welcome to the DexCom's CEO, Jake Leach. It's his first time as President and CEO up on stage here. Jake?Jacob LeachPresident, CEO & Director All right. Good morning, everybody. Thank you, Robbie. It's an absolute privilege to be able to kick off the conference this year, particularly as my first year as Pres ...

GE HealthCare Technologies (NasdaqGS:GEHC) FY Conference January 13, 2026 01:30 PM ET Company ParticipantsJay Saccaro - CFOPeter Arduini - CEOConference Call ParticipantsRobbie Marcus - AnalystRobbie MarcusGood morning, everyone. I'm Robbie Marcus, the MedTech Analyst at JPMorgan. Very happy to have our next session led by CEO of GE HealthCare, Peter Arduini. Peter will do a presentation, followed by some Q&A. Pete.Peter ArduiniThanks, Robbie. I guess it's still good morning, good afternoon for those on the ...

PresentationHi, everyone. My name is Rohin Patel. I'm a med tech analyst at JPMorgan. It's my pleasure to have Haemonetics here with us. And I'd like to introduce CEO, Chris Simon, for a presentation.Christopher SimonCEO, President & Director Thanks, Rohin, and thank you to JPMorgan for hosting the conference and giving us an opportunity to discuss our strategy and plans for long-term shareholder value creation. Thank you all for joining, both here in the room and on the WebEx. First point, just a necessar ...

SAN FRANCISCO--(BUSINESS WIRE)--Bunkerhill Health today announced the system-wide deployment of its Carebricks platform at the University of Texas Medical Branch, enabling clinician-led, agentic AI workflows that support care delivery across a health system serving over one million patient visits annually. Over the past year, UTMB Health has moved beyond isolated AI initiatives by deploying Bunkerhill's Carebricks platform to translate clinician- and operator-led ideas into system-wide action. ...

JP Morgan 44th Annual Healthcare Conference January 13, 2026 © 2026 Haemonetics Corporation Important Information Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "will," "should," "could," "would," "expect ...

Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its dip into bear territory in April. Market leadership continued to narrow as Mega-cap stocks and AI-driven companies dominated the lands ...

Valued at a market cap of $48.2 billion, Edwards Lifesciences Corporation (EW) is a medical technology company based in Irvine, California. It develops, manufactures, and markets advanced devices used to treat patients with serious heart conditions. The company is scheduled to announce its fiscal Q4 earnings for 2025 in the near future. Ahead of this event, analysts expect this healthcare company to report a profit of $0.61 per share, up 3.4% from $0.59 per share in the year-ago quarter. The company has ...

Core Insights - Diagnos Inc. is advancing its AI platform CARA for early detection of eye-related health issues and is focused on securing regulatory approvals in Canada, the U.S., and Saudi Arabia [1][2][6] Regulatory Pathway - The company is actively working to meet the regulatory standards in three key jurisdictions: Canada, the U.S., and Saudi Arabia [2] - In Saudi Arabia, CARA has been formally submitted for marketing approval to the Saudi Food and Drug Authority (SFDA) [6] - In Canada, the company is engaged with Health Canada to align with medical device regulations and plans to submit a formal application for CARA in the current quarter [6] - In the U.S., after strategic meetings with the FDA, the company has clarified the requirements for obtaining 510(k) clearance, facilitating the path to commercialization [6] Company Overview - Diagnos Inc. is a publicly traded Canadian corporation focused on the early detection of critical eye-related health problems using Artificial Intelligence [3] - The company's goal is to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [3]